Blood pressure response to melatonin in type 1 diabetes

Area of Science:

• Cardiovascular physiology
• Endocrinology
• Pediatric diabetes research

Background:

• Diminished nocturnal blood pressure decline is linked to cardiovascular disease risk.
• Exogenous melatonin administration lowers blood pressure in healthy adults.

Purpose of the Study:

• To investigate if melatonin enhances the sleep-related decrease in blood pressure among adolescents with type 1 diabetes.
• To assess the effect of melatonin on nocturnal blood pressure regulation in this specific patient group.

Main Methods:

• A randomized, placebo-controlled, double-blind crossover study involving 11 adolescents with type 1 diabetes and 10 healthy controls.
• Ambulatory blood pressure monitoring every 20 minutes for 24 hours before and during melatonin or placebo treatment.
• Analysis of blood pressure during sleep, wake, and 24-hour periods, accounting for sleep variables.

Main Results:

• Melatonin treatment led to a significantly greater decline in diastolic blood pressure during sleep in adolescents with type 1 diabetes compared to placebo.
• No significant effect of melatonin on blood pressure decline was observed in the healthy control group.
• No significant adverse side effects were reported during the study.

Conclusions:

• Melatonin effectively amplifies the nocturnal decrease in diastolic blood pressure in adolescents with type 1 diabetes.
• Further research, including dose-response studies, is recommended to explore melatonin's potential in preventing hypertension in type 1 diabetes.
• Melatonin should be considered for future clinical trials focused on hypertension prevention in type 1 diabetes.